Selected article for: "BBB blood brain barrier and blood brain barrier"
Author: Mignani, Serge; Shi, Xiangyang; Karpus, Andrii; Majoral, Jean-Pierre
Title: Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs
  • Cord-id: dw6m8zdd
  • Document date: 2020_10_11
    • ID: dw6m8zdd
    Snippet: There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and consequently, many neurological diseases remain undertreated. For past decades, to circumvent this effect, several nanocarriers have been developed to deliver drugs to the brain. Importantly, intranasal (IN) administration can allow direct delivery
    Document: There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and consequently, many neurological diseases remain undertreated. For past decades, to circumvent this effect, several nanocarriers have been developed to deliver drugs to the brain. Importantly, intranasal (IN) administration can allow direct delivery of drugs into the brain through the anatomical connection between the nasal cavity and brain without crossing the BBB. In this regard, dendrimers may possess great potential to deliver drugs to the brain by IN administration, bypassing the BBB and reducing systemic exposure and side effects, to treat diseases of the CNS. In this original concise review, we highlighted the few examples advocated regarding the use of dendrimers to deliver CNS drugs directly via IN. This review highlighed the few examples of the association of dendrimer encapsulating drugs (e.g., small compounds: haloperidol and paeonol; macromolecular compounds: dextran, insulin and calcitonin; and siRNA) using IN administration. Good efficiencies were observed. In addition, we will present the in vivo effects of PAMAM dendrimers after IN administration, globally, showing no general toxicity.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute administration: 1, 2
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and ad disease: 1, 2
    • absorption enhance and active drug: 1
    • absorption time and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • absorption time and adequate bioavailability: 1
    • accurately quickly and acute respiratory syndrome: 1, 2, 3, 4
    • acetate buffer and acute respiratory syndrome: 1
    • active drug and acute administration: 1
    • active drug and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active drug and ad disease: 1, 2
    • active principle and acute respiratory syndrome: 1, 2
    • acute respiratory syndrome and ad disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18